NeuroBo Pharmaceuticals (NRBO) Projected to Post Quarterly Earnings on Thursday

NeuroBo Pharmaceuticals (NASDAQ:NRBO) is projected to release its earnings data on Thursday, March 27th. Analysts expect NeuroBo Pharmaceuticals to post earnings of ($0.89) per share for the quarter.

NeuroBo Pharmaceuticals Price Performance

Shares of NRBO stock opened at $1.55 on Tuesday. NeuroBo Pharmaceuticals has a 1-year low of $2.08 and a 1-year high of $5.30. The company has a 50-day moving average of $1.70 and a two-hundred day moving average of $2.29.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.